HTSC·2026-03-24 07:41Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 22.53 [1][5] Core Insights - The company reported a revenue of RMB 575.2 billion for 2025, a decrease of 1.6% year-on-year, and a net profit attributable to shareholders of RMB 7.16 billion, an increase of 1.5% year-on-year, aligning with market expectations [1] - The revenue and profit growth showed marginal improvement compared to the first three quarters of 2025, driven by resilient performance in the pharmaceutical and medical device distribution sectors, as well as effective cost control measures [1] - The outlook for 2026 remains positive, with expectations for continued net profit growth due to ongoing structural optimization in distribution and retail operations [1] Summary by Sections Pharmaceutical Distribution - The pharmaceutical distribution segment generated revenue of RMB 435.4 billion in 2025, down 2.02% year-on-year, with an operating profit margin of 2.73% remaining stable compared to the previous year [2] - The segment is expected to stabilize in 2026, supported by ongoing optimization of product categories and strengthening direct sales to high-tier hospitals and retail terminals [2] Medical Device Distribution - The medical device distribution segment reported revenue of RMB 115.5 billion in 2025, also down 2.02% year-on-year, primarily due to intensified procurement policies [3] - The outlook for 2026 is optimistic, with expectations for increased focus on high-value business and expansion of SPD (supply chain distribution) projects, which saw double-digit revenue growth [3] Retail Business - The retail segment achieved revenue of RMB 38.4 billion in 2025, reflecting a year-on-year increase of 6.67%, driven by the performance of professional pharmacies [4] - The segment's operating profit margin improved to 1.56%, with significant cost control measures contributing to reduced losses in the Guoda Pharmacy chain [4] Profit Forecast and Valuation - The company is projected to have EPS of RMB 2.50, RMB 2.71, and RMB 2.89 for the years 2026, 2027, and 2028 respectively, with a PE ratio of 8.2x for 2026 [5][10] - The target price remains at HKD 22.53, reflecting a valuation based on 8.5 times the 2025 PE [5]